Daiichi Sankyo and Merck, also known as MSD internationally, have broadened their current global collaboration agreement to include Merck's MK-6070, an experimental T-cell engager aimed at delta-like ligand 3 (DLL3), alongside three...
Ocugen, Inc., a biotech company specializing in innovative gene and cell therapies and vaccines, disclosed that FDA has granted approval to initiate its expanded access program for using OCU400 on adult patients, 18 years and above, with retinitis...
Mallinckrodt plc, a worldwide specialty pharmaceutical company, and CVC Capital Partners, a top investment firm, have confirmed a deal where CVC Capital Partners Fund IX will buy the company's Therakos business for $925 million with standard...
Tecelra (afamitresgene autoleucel), a gene therapy, has been approved by the FDA for treating adults with unresectable or metastatic synovial sarcoma. Patients must have received prior chemotherapy, be positive for specific HLA antigens, and have...
European Medicines Agency (EMA) initiated a pilot program for expert panels to assist in the creation and evaluation of rare medical devices in the EU. The pilot program provides free guidance from medical device expert panels to specific...
Chugai Pharmaceutical Co., Ltd. reported the announcement of Chugai Pharma Taiwan Ltd. Chugai's subsidiary CPT received a license from TFDA to import Alecensa for ALK-positive NSCLC patients post-tumour resection. CPT manages the development...
MiRus, a company in the life sciences industry, has been granted Breakthrough Device Designation by the FDA for its EUROPA Posterior Cervical System, which uses its unique rhenium alloys, to treat issues in the cervical and upper thoracic spine...
NeuroBo Pharmaceuticals, Inc., a biotech company in the clinical stage that specializes in addressing cardiometabolic diseases, revealed the completion of a unique licensing deal with MThera Pharma Co., Ltd. (MTHERA) has the rights to NB-01 for...
Sanofi, a pharmaceutical company from France, announced that the Central Drugs Standard Control Organization (CDSCO) in India has approved the marketing of their new treatment Beyfortus for newborns and infants with respiratory syncytial virus...
Johnson & Johnson stated that the FDA has given approval for Darzalex Faspro to be used in combination with D-VRd for induction and consolidation in eligible NDMM patients for ASCT. Patients will be able to get this Darzalex Faspro-containing...
, CDSCO.jpg)
.jpg)